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In accordance with the current standards of treatment of breast cancer patients, the application of breast conserving 
treatment (BCT) requires a radical resection of the tumour and post-operative radiotherapy. This means the necessity 
of obtaining tumour-free primary resection margins, i.e. without the presence of cancer tissue. In spite of the cor-
rect pre-operative diagnostic process and appropriate surgical treatment, in about 20–30% BCT cases, the tumour 
resection turns out to be not radical. The necessity of performing another surgery leads to the prolongation of the 
overall operative time and increases costs. 
A histopathological evaluation of the margin of the primary tumour resection performed on an immediate basis is not 
a standard procedure in patients undergoing BCT. In spite of the definite limitations of this method, its application 
may decrease the overall rate of revision surgeries. The paper discusses some other currently available possibilities 
of perioperative evaluation of the radicality of primary tumour resection in breast cancer patients treated with BCT.
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Introduction 
In accordance with the current standards of treatment of 
breast cancer patients, the application of breast conserving 
treatment (BCT) requires a radical resection of the tumour 
and post-operative radiotherapy. This means the necessity 
of obtaining tumour-free (“clean”) primary resection mar-
gins, i.e. without the presence of cancer tissue (“no ink on 
the tumour” or “no tumour on the ink” — in accordance 
with the definition of the National Surgical Adjuvant Breast 
and Bowel Project — NSABP, the recommendations of the 
Society of Surgical Oncology — SSO and of the American 
Society for Radiation Oncology — ASTRO) [1–6]. 
A consequence of such definition of the correct manner 
of tumour resection is the loss of the clinical and therapeutic 
significance of other terms defining the scope of the primary 
tumour resection, such as “close margin”, “focally positive 
margin”). The first term (“close margin”) corresponded to 
margin of the tissues not affected by the cancer with a 
width lower than 2 mm. According to the results of the 
studies carried out by Bolger et al., this meant a statistically 
higher risk of the presence of additional tumour foci in the 
post-operative cavity [7]. The term “focally positive margin” 
meant the presence of ink on the surface of the tumour (irre-
spective of the type of tissue) on an area smaller than 4 mm. 
Following the Dutch Guidelines for Breast Cancer Tre-
atment, qualification of patients for adjuvant radiotherapy 
(within the classical BCT), without the necessity of radicali-
sation of the tumour resection, was possible [8].
In spite of the correct pre-operative diagnostic process 
and appropriate surgical treatment, in about 20–30% BCT 
cases, the tumour resection turns out to be not radical [9]. 
This means the necessity to re-operate on such patient. 
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In case of breast intraductal cancer in situ (carcinoma intra-
ductale — DCIS) this rate might be higher, amounting to 
31–46% [10–12]. In the case of an invasive form of cancer, 
co-existing with DCIS — it is 11–46% [13–15].
Apart from the prolongation of the overall treatment 
period and the increase of the costs, a re-operation of a BCT 
patient may lead to a higher rate of complications related to 
the treatment [16]. Additional surgery may also contribute 
to the discomfort felt by the patient, including lower quality 
of life. An important problem also related to the necessity 
of re-operation may by the risk of obtaining a poorer final 
aesthetic treatment effect [16].
One of the possibilities of the evaluation of the radicality 
of cancer resection during BCT is a histopathological veri-
fication of the tumour resection margins, performed on an 
immediate basis. The most frequently used method consists 
of a microscopic analysis of frozen specimens. In contrast 
to final histopathological evaluation (on the basis of the 
comparison of microscopic specimens made from paraffin 
blocs), the perioperative verification of the condition of the 
surgical margins does have some limitations. They concern, 
first of all, a lower sensitivity of the examination (65–78%). 
Moreover, such an evaluation extends the overall operative 
time [17–19]. 
In accordance with the current recommendations, 
a peri-operative assessment of the resection margins is not 
a standard course of treatment in a patient undergoing BCT. 
This concerns, first of all, the treatment of DCIS-type lesions, 
in the case of which the use of immediate pathological 
evaluation of the specimen should be avoided [4].
So far no generally accepted level of re-operation in 
patients with baseline BCT has been definitely established. 
In the opinion of majority of authors, the re-operation rate 
may be regarded as an indicator of the quality of care in 
breast cancer patients [14]. With regards to the multiple 
causes of this phenomenon, expanding the tumour resec-
tion margins does not reflect directly the efficiency of the 
primary surgery, seems to be prevailing [20–22].
Alternative methods of the evaluation of the 
quality of surgical margins in patients with 
breast conserving therapy 
General data 
An immediate verification of the radicality of the BCT 
surgery may consist of an in vivo evaluation of the tumour 
cavity or the assessment of the condition of the margins of the 
surgical specimen. With regards to the still unresolved tech-
nical limitations, the first of the listed possibilities is usually 
limited to attempts undertaken within clinical trials. Hence, 
the latter of the methods of evaluation of the quality of care 
in BCT proves to be more available and more widely applied. 
Apart from the perioperative pathological assessment of 
the primary tumour margins, made with the use of the fresh 
frozen specimens, there are other, alternative possibilities of 
determination of the radicality of the procedure. They differ 
from each other by the type of diagnostic method and the 
frequency of clinical application. These methods comprise 
some other types of pathological assessment, radiological 
(imaging), fluorescent, optical and isotopic methods. Also 
some other surgical procedures undertaken during the re-
section must be mentioned (additional margin resection 
and gross clinical evaluation of the specimen).
Pathological assessment methods 
An alternative to a perioperative pathological evaluation 
of the primary tumour resection margin is “touch imprint 
cytology” or “touch prep”. This modality may also be useful 
during a sentinel node biopsy in patients with a lower stage 
of breast cancer. This study applies the characteristic pro-
perty of cancer cells to adhere to clean glass surfaces and 
is not observed in the case of adipose cells [17].
Unlike immediate histopathological verification, the 
time necessary for touch imprint cytology is significan-
tly shorter [23]. However, this possibility of applying both 
diagnostic methods requires some additional skills from 
a pathologist. As it was seen in the studies performed by 
Esbony et al., in the centres with in-depth experience of 
perioperative cytology, this examination has high sensitivity 
(80–100%) and high specificity (85–100%) [23]. 
The evaluation of the radicality of the breast cancer 
resection may also be performed by means of macroscopic 
margin assessment (MMA) performed on an immediate 
basis. This assessment consists of determination of the di-
stance between the lesion and the edges of the resected 
specimen, after previous staining of the specimen surface 
with an ink or other dye. Once a margin with a width below 
5 mm is found (the measurement concerns any of the radial 
margins: superior, inferior, lateral and medial), the scope of 
the tumour excision must be immediately extended in the 
appropriate direction [7, 24]. In accordance with the results 
of the studies, the application of MMA in patients undergo-
ing BCT decreases the rate of re-operations in comparison 
with the group of patients operated without the application 
of this method (26% vs 34%) [7].
Radiological (imaging) techniques 
A large group of applications of the imaging methods for 
the assessment of surgical margins is an outcome of the use 
of radiological examination for the pre-operative diagnostics 
of breast cancer. This is also an effect of the consensus of 
opinion-forming groups of experts. In accordance with the 
current recommendations of the Polish Society of Oncological 
Surgery, concerning breast cancer treatment, “it is recommen-
ded to perform a perioperative imaging assessment (mammo-
graphy/ultrasound) in order to confirm a radical resection of 
the lesion. A peri-operative imaging assessment is performed 
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with the same method which was used for the pre-operative 
identification of a lesion. In the case when a perioperative as-
sessment shows that the lesion has not been resected or has not 
been resected radically, it is necessary to resect the proper lesion 
or its missing part during the same surgery and then repeat the 
peri-operative imagining assessment” [4].
A mammographic verification of the margins of the re-
sected tissue specimen has become a standard procedure in 
the majority of centres. It allows a surgeon to obtain, in real 
time, information about the radicality of the performed pro-
cedure or about the necessity to extend its scope [25–27]. 
There is, however, some discrepancy of views concerning the 
clinical value of the specimen evaluated with this method. 
In the opinion of Britton et al. [26] and of Edwards et al. [28], 
this is the most useful method of verification of the resection 
margins out of all radiological assessment techniques. This 
view is additionally confirmed by the recommendations of 
SSO-ASTRO, concerning patients requiring a pre-operative 
staining of an extensive area of micro-calcifications with the 
use of bracketing. According to these recommendations, 
in the above group of patients it is necessary to perform 
a mammographic assessment after the resection in order to 
exclude the presence of residual lesions in the breast [3, 29].
Some other authors in turn, regard the correlation be-
tween the mammographic image and the result of the pa-
thological report as highly unsatisfactory in a large number 
of cases [7, 25].
Another method of imaging assessment of the radicality 
of the primary tumour resection in BCT is a peri-operative ul-
trasound (USG). This concerns, in particular, the possibility of 
application of high-frequency ultrasound devices. As it has 
been seen in numerous clinical studies, such an assessment 
makes it possible to verify the resection margins of patholo-
gical lesions in a credible way as well as to differentiate these 
lesions in an accurate way [30, 31]. In accordance with the 
results of the works carried out in 2013–2016 at the National 
Cancer Institute in Bangkok, which consisted in the ultra-
sound assessment of surgical specimen, this examination is 
characterised with very high sensitivity. After the conside-
ration of the result of the final assessment of the radicality 
in a histopathological examination, the correlation of both 
methods was confirmed in 93.6% of patients with solitary 
tumours. In the group of patients with multiple lesions, the 
rate of correct assessment of surgical margins in the ultraso-
und was lower, yet still it was at a satisfactory level (in 75% 
of studied patients). The authors point to a very high level 
of radicality of breast conserving procedures performed in 
their centre. More than 95% of patients treated in this way 
did not require a secondary procedure, which was also the 
result of the peri-operative ultrasound assessment of the 
surgical margins [30]. Some other studies show, however, 
that a more useful method for this purpose is verification 
with the use of a peri-operative mammography [28].
Thanks to the introduction of miniaturised and mobile 
devices, it is possible now to apply another imaging method 
in the operating theatre — magnetic resonance imaging (MRI). 
As was shown in the studies of Papa et al., the high sensitivity of 
the technique (71–100%), which was previously used mostly for 
diagnosing breast cancer (especially in high-risk populations), 
may be additionally used for the evaluation of the radicality 
of the BCT procedure. The ClearSightTM system, used by the 
authors, allows to evaluate ex vivo tissue specimens (after the 
tumour resection). A short measuring time (1–2 seconds) allows 
for the verification of the tumour margins, performed in real 
time. As opposed to standard MRI devices, the system does 
not require additional shields. Some special attention must 
be paid to the high value of this technique in differentiating 
between healthy tissues and cancer infiltration. According to 
the presented results, the sensitivity of the examination was 
91%, specificity — 93%, accuracy — 92% (with the AUC value 
being 0.97). The above measurements were taken on a small 
group of 22 subjects undergoing BCT. Therefore, the results 
require confirmation in further studies [32].
A method that has a similarly limited clinical imple-
mentation is optical coherence elastography (OCE). During 
a peri-operative assessment of the resected specimen, the 
degree of tissue deformation, caused by mechanical pres-
sure, is made. A characteristic property of malignant lesions, 
used for their differentiation, is their mechanical heteroge-
nicity. The obtained data are presented in a graphic form 
(elastogram). They also require comparison with the images 
obtained with the standard tissue staining techniques (ha-
ematoxylin and eosin/H&E/stain) [33, 34].
Fluorescence techniques 
In order to apply this group of diagnostic techniques, 
it is necessary to use fluorophores (chemical compounds 
which fluorescence properties induced by light excitation, 
i.e. by infrared light) and the appropriate equipment [35–38], 
comprising a source of light with a specific wavelength — 
light-emitting diode (LED), a charge-coupled device (CCD), 
which works as a detector of the generated radiation as well 
as a monitor which makes it possible to track the image 
during the procedure. Apart from the known clinical ap-
plications (mapping the lymphatic system in oncological 
surgery, plastic and reconstructive surgery, cardiac surgery 
and transplantology) [38], this method has proven to be 
useful for evaluation of the surgical margins of tumour resec-
tion during BCT [35, 36]. The most frequently used tracer is 
indocyanine green (ICG), which has a fluorescence capacity 
in infrared light with a wavelength of 800–840 nm. As was 
shown by Kennedy et al., the administration of ICG directly 
into the cancer lesion and to the subcutaneous tissue lying 
below it, allows for a credible evaluation of the surgical 
margins. The sensitivity of the method, as confirmed by 
the authors was about 70%, whilst specificity was 85% [36]. 
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The introduction of the OST GAINS technique (optical 
see-through goggle augmented imaging and navigation 
system) is a continuation of the method based on the use 
of the LED-CCD devices. Technological progress has made 
it possible to replace the system registering the effect of the 
indocyanine green fluorescence (camera, monitor) with the 
goggles worn by a surgeon. The largest advantage of the new 
solution is its increased mobility and the fact that the operator 
is independent from the assistant, whilst the former clinical 
value of the method is still preserved. In accordance with the 
suggestion of the authors of the studies carried out with the 
use of the OST GAINS technique, it is necessary to continue 
these studies on a larger group of subjects [39]. 
The use of fluorescence methods is possible also thanks 
to the more frequent occurrence of overexpression of 
VEGF-A (vascular endothelial growth factor) in breast cancer 
patients. This overexpression is diagnosed in a significantly 
higher rate of breast cancer cases than the overexpression 
of the HER2 receptor (human epidermal growth factor re-
ceptor 2: in about 73% and 10–20% cases respectively). This 
allows for the possibility of using a complex consisting of 
an appropriate antibody (bevacizumab) and a fluorescent 
substance (IRDye800CW) as the tracer. The IRDye800CW 
fluorescence occurs within the scope of near infrared light 
with a wavelength of 770–800 nm. In the study carried out 
by Lamberts et al., which was the first clinical attempt to 
use the combination of bevacizumab and IRDye800CW on 
a human model for the purpose discussed here, the efficacy 
of this method was confirmed. The obtained values of the 
tracer accumulation level within the tumour, its nearest 
margins and in the tissue not affected by the tumour were 
characterised by statistically significant differences (p < 0.05 
and p < 0.0001, respectively). The tests were carried out 
on a group of 19 breast cancer patients, 20 assessments 
of the resected cancer lesions were performed altogether 
(11 tissue specimens from tumorectomy and 9 tissue spe-
cimens after mastectomy were used). However, a limited 
performance of the technique with regards to the possi-
bility of diagnosing DCIS type lesions within the specimen 
margins was observed. As the authors suggest, in order to 
improve the sensitivity, it is necessary to use a larger dose 
of bevacizumab. Currently it is still not possible with regards 
to the limitations concerning the use of this antibody for 
extra-therapeutic purposes established by the FDA (Food 
and Drug Administration) [40]. 
Optic techniques 
All diagnostic methods belonging to the group of optic 
techniques share one property i.e. the necessity to interpret 
the observed light spectrum (spectroscopy), in structural 
verifications. In order to evaluate the condition of the tis-
sues which surrounded the resected tumour, the following 
techniques can be applied: diffuse reflection spectroscopy, 
fluorescence spectroscopy, optical coherence spectrosco-
py, bio-impedance spectroscopy, Cerenkov luminescence 
imaging, Raman spectroscopy (the measurement of Raman 
radiation scattering — non-elastic photon scattering). Some 
of the modalities listed here are the methods in which, 
apart from spectroscopy, some other physical phenomena 
are applied as well (fluorescence spectroscopy, Cerenkov 
luminescence).
In order to perform the analysis of diffuse reflectance 
spectroscopy (DRS), it is necessary to measure light waves 
with the length of 400–1600 nm. As it is seen in the studies 
of de Boer et al., this method is valuable in differentiating 
between normal tissues and cancer infiltration. The authors 
confirmed the sensitivity of the examination to be 74–79%; 
specificity — 78–93% (the AUC value being 0.94). The results 
were comparable both for the measurements performed in 
in vivo, and ex vivo conditions, which adds to the value of the 
test. The lack of necessity to use additional light-sensitive 
or radioactive substances (as in the fluorescence or isotope 
methods) is an additional attention-deserving advantage of 
the test. Some drawbacks of this modality is the effect of the 
menopausal status of the patient and the type of normal tis-
sues, unaffected by the cancer, on the obtained results [41]. 
Another clinically available modality is bio-impedance 
spectroscopy. This technique is based on the variability of 
dielectric properties of various types of tissues. The practical 
application of the method is obtained thanks to the Clear-
Edge device. This examination allows for a high-sensitivity 
diagnosis of DCIS lesions within the resection margins. Its 
value does not depend on the structure type of the breast 
gland (similar results were obtained both for glandular and 
adipose tissues). According to Dixon et al., the most impor-
tant advantage of this method is a short learning curve and 
the possibility of obtaining the final result in a very short 
time (within 5 minutes, which is identical with the possi-
bility of rendering real-time images) [42]. Also the facility 
of using the ClearEdge is stressed here, gained thanks to 
the small size of the device, the cordless system and the 
availability of the colour-coded image (rendered on an LCD 
displayer). This technique allows for measurements up to 
the depth of examined tissues of 3 mm, which sufficiently 
meets the diagnostic expectations. As it was shown in the 
clinical studies, the use of this method, decreases the rate 
of reoperations after BCT, even in as many as 50% cases. 
Additionally, this method, as one of the few modalities used 
for the verification of the resection margins of the primary 
tumour, allows to evaluate the BCT tumour cavity in a uni-
que manner. The cavity is scanned with a disposable sterile 
working headpiece of the device [42].
The last of the optical methods discussed in this paper, 
applies Cerenkov luminescence. This is a type of electroma-
gnetic radiation (in a form of photons), emitted by a dielec-
tric medium, within which the particles with electric charges 
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(positrons or electrons) are moving within this medium with 
the speed higher than the speed of light. The discovery of 
this type of radiation was awarded in 1958 with the Nobel 
prize in physics (the awarded team: Pavel Cerenkov, Il’ja 
Mikhailovic, Frank and Igor Yevgenyevich Tamm). 
In accordance with the results of the studies carried out by 
Grootendorst et al., in the methods based on Cerenkov lumi-
nescence, it is possible to use tracers, specific for a particular 
type of tumour (used also in PET — Positron Emission To-
mography and SPECT — Single-Photon Emission Computed 
Tomography), which increases the value of this method [43]. 
The most frequently used tumour marker is fludeoxyglucose 
(18F-FDG). The possibility of applying this method in the ope-
rating theatre is the outcome of the accessibility of the mobile 
PET devices (equipment miniaturisation). However, currently, 
this evaluation of the breast tumour resection margins has 
some limitations. The time span of the evaluation is still very 
long. There are also difficulties in obtaining an image with an 
appropriate resolution (being the outcome of the artefacts 
resulting from the manipulations of the manually-controlled 
device and from the respiratory movements of the chest and 
GI tract motility) [43].
Isotope methods 
As opposed to the above-listed methods of evaluation 
of the radicality of primary tumour resection, isotope exami-
nations require the application of ionizing radiation, which is 
the core problem voiced by the advocates of other methods 
of verification of the condition of surgical margins.
The marker which is the most frequently used out of all the 
diagnostic markers in this group is 111In or 89Zr radio-labelled 
bevacizumab [40, 44]. With regards however to the high requ-
irements concerning the necessary equipment, as well as the 
necessity to meet the requirements of radiological protection, 
the attempts carried out to perform this type of evaluation are 
quite rare and concern limited groups of patients. 
Additional surgical procedures to be performed 
during surgical resection 
In order to minimize the risk of non-radical resection of 
cancer during BCT, it is possible to perform a routine immediate 
resection of additional margins from the tumour cavity (cavity 
shave margins — CSM). In accordance with the recommenda-
tions concerning this method, it is necessary to obtain at least 
four specimens (corresponding to the superior, inferior, lateral 
and medial margin), each with a minimum width of 1 cm [45]. 
In the opinion of Kobbermann et al. it is necessary to resect 
also the margin on the side of the skin (anterior margin) and 
on the side of the fascia of the pectoral major muscle (poste-
rior margin) [46]. The above course of treatment is especially 
helpful in the case of treatment of the breast multi-nodular 
cancer lesions, undiagnosed preoperatively [7, 46]. As it was 
seen from the studies carried out by Bolger et al., in group of 
patients undergoing BCT, a significantly lower rate of necessary 
re-operations was observed in those with CSM (24% vs 34% 
— in the subjects without CSM) [7]. This observation has also 
been confirmed by other authors [47, 48].
A generally applied method of evaluation of the radicali-
ty of the BCT procedure is a gross clinical assessment of the 
lumpectomy specimen. It is used both for the examination 
of the tissue specimen and also for the evaluation of the 
walls of post-surgical cavity, which frequently indicates the 
Table I. Alternative possibilities of peri-operative evaluation of the conditions of primary cancer resection margins in breast cancer patients undergoing BCT
Type of immediate evaluation of 
resection margin 
Advantages of the method Limitations of the method 
Methods of pathological evaluation (touch 
imprint cytology, macroscopic evaluation 
of resection margins)
– large accessibility
– low cost 
– high sensitivity and specificity 
– necessity to be evaluated by an experienced 
pathologist 
Radiological methods:
– classical (MMG, USG)
– the examination of the magnetic 
resonance, optical coherence 
elastography
– large accessibility (the standard if imaging 
evaluation of the surgical specimen)
– low cost
– procedures with low degree of complexity 
– high sensitivity and specificity
– limited sensitivity 
– significantly limited accessibility
– complexity 
– high cost 
Fluorescence methods – high sensitivity and specificity – significantly limited accessibility 
– complexity 
– high cost
Optical methods – high sensitivity and specificity – significantly limited accessibility 
– complexity 
– high cost




necessity to perform an immediate extension of the scope 
of primary tumour resection. It seems, however, that in spite 
of significant advantages (short time and simplicity of the 
procedure), this type of evaluation of the quality surgical 
margins is the least efficacious method out of all modalities 
discussed in this paper [7]. 
Final remarks 
Peri-operative evaluation of the tissue margins of the 
surgical specimen after BCT is a definitely required tre-
atment standard [4]. The choice of diagnostic method is 
a derivative of the equipment and logistic possibilities of 
oncological centres specialising in breast cancer treatment. 
The evaluation of the harvested tissues performed solely by 
the operating surgeon is unacceptable. 
Given the economic limitations concerning the prin-
ciples of operation of healthcare institutions in Poland, it 
seems justified, in the opinion of the authors, to perform the 
classical radiological evaluation (MMG, USG) as a priority. An 
alternative method of verification of radicality of BCT, may 
be the gross clinical evaluation of the margins performed 
by a pathologist. The clinical information obtained due to 
the additional evaluation of the specimen may, at least in 
some of the cases, protect the patients against the necessity 
of undergoing another surgery. 
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